Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.
Development of new drugs for personalized cancer chemotherapy
In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.
10, rue de l'Espinay
D0-705C
Québec, Québec
Canada G1L 3L5
- Bouzriba, ChahrazedDoctoral studentchahrazed.bouzriba.1@ulaval.cachahrazed.bouzriba@crchudequebec.ulaval.ca
- Bruxelles, QuentinDoctoral studentCHUL+1 418-525-4444, extension 52425quentin.bruxelles@crchudequebec.ulaval.ca
2705, boulevard Laurier
P-9800
Québec, QC
Canada G1V 4G2 - Chavez Alvarez, Atziri CorinDoctoral studentatziri-corin.chavez-alvarez.1@ulaval.caatziri-corin.chavez-alvarez@crchudequebec.ulaval.ca
- Hamel-Côté, GenevièveEmployeegenevieve.hamel-cote@crchudequebec.ulaval.ca
- Ouellette, VincentDoctoral student+1 418-525-4444, extension 52364vincent.ouellette@crchudequebec.ulaval.ca
- Ringuette, JoanieMaster studentHôpital Saint-François d'Assise+1 418-525-4444, extension 52425joanie.ringuette@crchudequebec.ulaval.ca
10, rue de l'Espinay
D0-705
Québec, QC
Canada G1L 3L5
Synthetic development of sugar amino acid oligomers towards novel podophyllotoxin analogues
Journal ArticleBioorg Med Chem, 52 , 2021.
Abstract | Links: 
Phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonates and phenyl 4-(2-oxopyrrolidin-1-yl)benzenesulfonamides as new antimicrotubule agents targeting the colchicine-binding site
Journal ArticleEur J Med Chem, 213 , 2021.
Abstract | Links:
Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugs
Journal ArticleJ Pharm Pharmacol, 72 (2), 2020.
Abstract | Links: 
N-phenyl ureidobenzenesulfonates, a novel class of promising human dihydroorotate dehydrogenase inhibitors
Journal ArticleBioorg Med Chem, 28 (22), 2020.
Abstract | Links:
Stereoselective Synthesis of Fluorinated Galactopyranosides as Potential Molecular Probes for Galactophilic Proteins: Assessment of Monofluorogalactoside-LecA Interactions
Journal ArticleChemistry, 25 (17), 2019.
Abstract | Links:
Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer
Journal ArticleJ Oncol Pharm Pract, 25 (1), 2019.
Abstract | Links:
Preparation, characterisation and biological evaluation of new N-phenyl amidobenzenesulfonates and N-phenyl ureidobenzenesulfonates inducing DNA double-strand breaks. Part 3. Modulation of ring A
Journal ArticleEur J Med Chem, 155 , 2018.
Abstract | Links:
Diversity-Oriented Synthesis of Diol-Based Peptidomimetics as Potential HIV Protease Inhibitors and Antitumor Agents
Journal ArticleChembiochem, 2018.
Abstract | Links:
4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells
Journal ArticleBioorg Med Chem, 26 (18), 2018.
Abstract | Links:
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells
Journal ArticleJ Med Chem, 60 (12), 2017.
Abstract | Links:
Active projects
- Développement et optimisation de nouveaux agents anticancéreux ciblant les cancers humains réfractaires aux traitements actuels., from 2023-07-01 to 2026-06-30
- Eleclazine: “Boosting” efficacy and safety of the antineoplastic drug Alpelisib (Piqray®)?, from 2023-01-01 to 2024-12-30
- L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
- Pharmacological optimization of OpKemo, a silica-based nanoparticle platform for oncology, from 2022-01-31 to 2024-12-31
Recently finished projects
- Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, from 2016-04-01 to 2023-03-31
- Computational design, synthesis, and screening of FUT8 inhibitors as new anticancer agents_Fortin, from 2022-09-01 to 2023-08-31
- Design and synthesis of FUT8 inhibitors as new anticancer agents - Fortin, from 2022-04-01 to 2023-07-31
- Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, from 2020-02-01 to 2024-01-31
- Projet parent « Design and synthesis of FUT8 inhibitors as new anticancer agents, from 2022-04-01 to 2023-07-31
- Soutien séjour en France - 8 au 18 mars 2024, from 2023-10-01 to 2024-04-30